



11/05/2020

To Whom It May Concern:

Please be advised that as of November 5, 2020, Sheridan Community Hospital will begin testing patients for the SARS-CoV-2 IgG antibody using the Beckman Coulter Access Immunoassay system. Testing will be available 24 hours a day with an expected turnaround time of 4 hours.

The Access SARS-CoV-2 IgG assay is intended for the qualitative detection of IgG antibodies to SARS-CoV-2 from individuals as an aid in identifying patients with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Access SARS-CoV-2 IgG assay should not be used to diagnose or exclude acute SARS-CoV-2 infection.

The sensitivity of the Access SARS-CoV-2 IgG assay early after infection is unknown. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing should be performed. Currently, Sheridan Community Hospital is collecting samples for diagnostic PCR testing; however, they are being sent to our reference lab for testing. Expected turnaround time for those results is approximately 48-72 hours.

If you should have any questions or concerns regarding this test, please don't hesitate to contact the lab.

Respectfully,

Michael Mull, MLS (ASCP)^{CM}
Laboratory Manager
Sheridan Community Hospital
301 N. Main St. Sheridan, MI 48884
CLIA# 23D0376148

Dr. Anna Puzanov
Laboratory Medical Director